Caribou Biosciences Announces FDA Clearance Of IND Application For CB-011, An Allogeneic Anti-BCMA CAR-T Cell Therapy For The Treatment Of Relapsed Or Refractory Multiple Myeloma

Press/Media

Period21 Nov 2022 → 22 Nov 2022

Media coverage

2

Media coverage